Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded by BidaskClub to Buy

0
34
planning savings money of coins to buy a home, concept for property ladder, mortgage and real estate investment. for saving or investment for a house, growing business

Agios Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Agios Pharmaceuticals Upgraded by BidaskClub on 6/30/2020. In a note to investors, the firm issued a new rating of Buy. The analysts previously had rating of Hold.

Shares of Agios Pharmaceuticals traded up $1.31 on Monday, reaching $53.02. 0 shares of the stock traded hands, compared to its average volume of 689676. Shares of Agios Pharmaceuticals ended Monday on at $53.02. The firm’s 50 day moving average is $47.67 and its 200 day moving average is $42.88.Agios Pharmaceuticals  has a 12 month low of $50.93 and a 12 month high of $54.68. While on yearly highs and lows, Agios Pharmaceuticals’s today has traded high as $53.84 and has touched $50.93 on the downward trend. See More Analyst Rating at: RATING

Agios Pharmaceuticals Earnings and What to expect: 

Agios Pharmaceuticals last announced its quarterly earnings data on April 30th, 2020. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.67) by $1.08. The business had revenue of $87.10 million for the quarter, compared to analysts’ expectations of $31.12 million. Its revenue was up 188.4% compared to the same quarter last year. Agios Pharmaceuticals has generated ($6.86) earnings per share over the last year. Agios Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, August 6th, 2020 based off prior year’s report dates.

Earnings for Agios Pharmaceuticals are expected to remain at ($4.67) per share in the coming year. The P/E ratio of Agios Pharmaceuticals is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Agios Pharmaceuticals is -8.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Agios Pharmaceuticals has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 3.16%
  • On 5/20/2020 Insider Christopher Bowden Sell 3,583 at average share price of $50.01 which equates to $179,185.83 in money value.
  • On 2/13/2020 Insider Christopher Bowden Sell 7,100 at average price of  $50.16 with total value of : Not Data Available
  • On 2/4/2020 Insider Christopher Bowden Sell 49,638 at average price of  $50.08 with total value of : $2,485,871.04

Analyst at BidaskClub are also talking about :

  • 6/30/2020 – Winmark was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – Vaxart was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – VSE was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/30/2020 – Verisign was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Agios Pharmaceuticals (NASDAQ:AGIO) Moving Average Technical Analysis

5 day Moving Average is $52.01 And 5 day price change is $4.80 (9.95%)  with average volume for 5 day average is 546,200. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $50.37 and 20 day price change is $0.92 (1.77%) and average 20 day moving volume is 677,755. 50 day moving average is $47.67  and 50 day price change is $7.63 ( 16.81%)  and with average volume for 50 days is : 742,648. 200 day moving average is $42.88  and 200 day price change is $14.87 (38.98%)  and with average volume for 200 days is : 771,883.

See More Analyst Rating at: RATING